Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)
| Status: | Active, not recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 3 - 25 |
| Updated: | 4/21/2016 |
| Start Date: | May 2007 |
| End Date: | December 2017 |
Feasibility of Using Concurrent Carboplatin and Reduced Dose Craniospinal Radiation (24Gy) for Metastatic Medulloblastoma, High-Risk Supratentorial PNET and Metastatic PNET
To study the efficacy of the combination of reduced dose craniospinal radiation (reduced
from standard of care dosing at 36 Gy to 24 Gy) with concurrent carboplatin and vincristine
administration for metastatic classical histology medulloblastomas and high-risk
supratentorial PNETs and metastatic PNETs.
from standard of care dosing at 36 Gy to 24 Gy) with concurrent carboplatin and vincristine
administration for metastatic classical histology medulloblastomas and high-risk
supratentorial PNETs and metastatic PNETs.
Inclusion Criteria:
- Age greater than 3 years and less than 25 years
- Patients with classic histology or desmoplastic histology metastatic medulloblastoma
by histological diagnosis and by head and spine MRI.
- Patients with anaplastic histology will be excluded.
- Patients with high-risk supratentorial, non-metastatic, PNET
- Patients with metastatic PNET
- Newly diagnosed patients who have not received prior therapy, with the exception of
one short course of emergent chemotherapy in newly presenting patients with
neurological compromise per provider decision
- Only patients who are expected to survive at least 6 weeks will be eligible for this
study.
Exclusion Criteria:
- Patients who are pregnant may not be treated on this study
We found this trial at
1
site
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
Click here to add this to my saved trials
